PCRX - Pacira BioSciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
37.95
+0.05 (+0.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close37.90
Open38.66
Bid0.00 x 900
Ask0.00 x 800
Day's Range37.22 - 38.31
52 Week Range35.07 - 55.00
Volume276,956
Avg. Volume512,100
Market Cap1.58B
Beta (3Y Monthly)0.50
PE Ratio (TTM)205.14
EPS (TTM)0.19
Earnings DateOct 30, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est52.29
Trade prices are not sourced from all markets
  • ASRT vs. PCRX: Which Stock Is the Better Value Option?
    Zacks

    ASRT vs. PCRX: Which Stock Is the Better Value Option?

    ASRT vs. PCRX: Which Stock Is the Better Value Option?

  • GuruFocus.com

    Pacira Biosciences Inc (PCRX) CEO and Chairman David M Stack Sold $503,038 of Shares

    CEO and Chairman of Pacira Biosciences Inc (30-Year Financial, Insider Trades) David M Stack (insider trades) sold 12,849 shares of PCRX on 08/15/2019 at an average price of $39.15 a share. Continue reading...

  • Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
    Zacks

    Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

    Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.

  • Pacira Pharmaceuticals, Inc. (PCRX) Q2 2019 Earnings Call Transcript
    Motley Fool

    Pacira Pharmaceuticals, Inc. (PCRX) Q2 2019 Earnings Call Transcript

    PCRX earnings call for the period ending June 30, 2019.

  • Pacira (PCRX) Beats Q2 Earnings and Revenue Estimates
    Zacks

    Pacira (PCRX) Beats Q2 Earnings and Revenue Estimates

    Pacira (PCRX) delivered earnings and revenue surprises of 20.59% and 2.80%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Pacira BioSciences Reports Second Quarter 2019 Financial Results and Business Update

    -- Total revenues increased 22% over prior year to $102.6 million in second quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 08,.

  • GlobeNewswire

    Pacira BioSciences to Present at the 2019 Wedbush Pacgrow Healthcare Conference

    PARSIPPANY, N.J., Aug. 07, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 2019 Wedbush Pacgrow Healthcare Conference at 12:45 PM ET.

  • Pacira (PCRX) Earnings Expected to Grow: Should You Buy?
    Zacks

    Pacira (PCRX) Earnings Expected to Grow: Should You Buy?

    Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Should You Be Concerned About Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Historical Volatility?

    If you own shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) then it's worth thinking about how it contributes to the...

  • GlobeNewswire

    Pacira to Report Second Quarter 2019 Financial Results on Thursday August 8, 2019

    Pacira BioSciences, Inc. (PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 8, 2019. International callers may dial 1-720-545-0035 and use the same passcode.

  • Zacks Small Cap Research

    DRRX: Favorable FDA Decision on POSIMIR Would Likely Mean Significant Upside to Our Model

    This morning, Durect (DRRX) announced that they submitted a full response to FDA’s Complete Response Letter for POSIMIR, which Durect received in February 2014. POSIMIR is the company’s investigational post-operative pain relief depot that utilizes the company’s patented SABER technology and is intended to deliver bupivacaine to provide three days of pain relief after surgery. As a reminder DRRX submitted an NDA ((via 505(b)(2) pathway)) to FDA for POSIMIR in April 2013.

  • Pacira Gets EMA Acceptance for Pain Management Drug Exparel
    Zacks

    Pacira Gets EMA Acceptance for Pain Management Drug Exparel

    The EMA authorizes Pacira's (PCRX) marketing application for Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

  • GlobeNewswire

    New Retrospective Analysis Shows EXPAREL Associated with Significantly Less Opioid Use Following Third Molar Extraction

    PARSIPPANY, N.J., June 26, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced results of a new analysis of patients undergoing elective third molar (“wisdom.

  • GlobeNewswire

    Pacira BioSciences Announces Validation of EXPAREL Marketing Authorization Application from European Medicines Agency

    Pacira BioSciences, Inc. (“Pacira”) (PCRX) today announced that the company’s Marketing Authorization Application (MAA) for EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical analgesia was validated by the European Medicines Agency (EMA).  With this validation, the Pacira application is complete and the EMA Committee for Medicinal Products for Human Use (CHMP) will now begin the review procedure with an opinion expected in the second half of 2020. “The validation of our MAA by the EMA is another major step forward in our effort to significantly expand patient access to EXPAREL-based opioid-sparing strategies,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences. “We have submitted a robust dataset demonstrating the efficacy of EXPAREL in infiltration, field block, and nerve block in both placebo-controlled and active comparator studies.

  • Is Pacira BioSciences, Inc. (NASDAQ:PCRX) Trading At A 36% Discount?
    Simply Wall St.

    Is Pacira BioSciences, Inc. (NASDAQ:PCRX) Trading At A 36% Discount?

    Today we will run through one way of estimating the intrinsic value of Pacira BioSciences, Inc. (NASDAQ:PCRX) by...

  • JAZZ or PCRX: Which Is the Better Value Stock Right Now?
    Zacks

    JAZZ or PCRX: Which Is the Better Value Stock Right Now?

    JAZZ vs. PCRX: Which Stock Is the Better Value Option?

  • GlobeNewswire

    Pacira BioSciences Appoints Former Johnson & Johnson Executive, Max Reinhardt, as President

    Pacira BioSciences, Inc. (PCRX) today announced the appointment of Max Reinhardt as the company’s president. Mr. Reinhardt will report to Dave Stack, chairman and chief executive officer of Pacira, and be responsible for overseeing all commercial and medical affairs functions at Pacira. Mr. Reinhardt was most recently Vice President of Marketing for DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, where he was accountable for $5.5 billion in revenue from its comprehensive portfolio of solutions for medical specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine.

  • Markit

    See what the IHS Markit Score report has to say about Pacira Biosciences Inc.

    Pacira Biosciences Inc NASDAQ/NGS:PCRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for PCRX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PCRX are favorable, with net inflows of $2.36 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Here’s What Hedge Funds Think About Pacira Pharmaceuticals Inc (PCRX)
    Insider Monkey

    Here’s What Hedge Funds Think About Pacira Pharmaceuticals Inc (PCRX)

    The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the […]

  • GlobeNewswire

    New Analysis Shows Use of EXPAREL Associated with Improved Clinical and Economic Outcomes Following Hip Replacement Surgery

    PARSIPPANY, N.J., June 12, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced new data on the use of EXPAREL® (bupivacaine liposome injectable suspension).

  • GlobeNewswire

    Pacira Announces Publication of Pivotal Study of EXPAREL as a Single-Dose Interscalene Brachial Plexus Nerve Block in Patients Undergoing Shoulder Surgery

    Pacira BioSciences, Inc. (PCRX) today announced the publication of its multinational Phase 3 study supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable suspension) as a single-injection interscalene brachial plexus nerve block (ISNB) in patients undergoing total shoulder arthroplasty or rotator cuff repair. The results demonstrate that EXPAREL significantly improved pain control and reduced opioid consumption through 48 hours compared with placebo and a standardized pain management protocol alone.